Chan Jeffery Ching Ho, Rosa Duque Jaime S, Durrheim David N, Tsang Thomas, Lau Yu Lung
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong
BMJ Glob Health. 2025 Jun 30;10(6):e018973. doi: 10.1136/bmjgh-2025-018973.
Following the development and roll-out of the measles vaccine in 1954, measles incidence dropped to low levels in areas where measles vaccines with high coverage were introduced. The Measles and Rubella Strategic Framework 2021-2030 developed by the Measles & Rubella Initiative aims to eliminate measles globally by 2030. However, there has been a resurgence of measles cases after the COVID-19 pandemic in many countries, including some in the Western Pacific Region. This review describes the journey from 1967, when Hong Kong introduced a single-dose regimen, to 2024 when Hong Kong had been experiencing an increase in imported measles cases despite being verified to have achieved measles elimination in 2016. Hong Kong's experience in maintaining high vaccination coverage and comprehensive surveillance may provide an exemplary framework for other countries in the Western Pacific Region.
1954年麻疹疫苗研发并推广后,在引入高覆盖率麻疹疫苗的地区,麻疹发病率降至低水平。麻疹和风疹倡议组织制定的《2021-2030年麻疹和风疹战略框架》旨在到2030年在全球消除麻疹。然而,在包括西太平洋区域一些国家在内的许多国家,新冠疫情后麻疹病例有所反弹。本综述描述了从1967年香港引入单剂次接种方案,到2024年香港尽管在2016年已被证实实现麻疹消除,但仍出现输入性麻疹病例增加的历程。香港在维持高疫苗接种覆盖率和全面监测方面的经验可能为西太平洋区域其他国家提供一个典范框架。